Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulation for glioblastoma.

David A Reardon1, Patrick Y Wen, Kai W Wucherpfennig

  • 1aCenter for Neuro-Oncology bDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts cDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA.

Current Opinion in Neurology
|April 4, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026
Same author

Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

A 10-year-long ongoing complete response to vismodegib as first-line treatment in adult metastatic medulloblastoma.

Acta oncologica (Stockholm, Sweden)·2026
Same author

Clinical validation of a high-performance somatic exome sequencing assay: from target-enrichment strategy to variant calling.

NPJ genomic medicine·2026
Same author

Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitors.

Neuro-oncology advances·2026

Immunotherapy shows promise for glioblastoma (GBM) treatment, but its role is still under investigation. Future development may involve combination therapies to overcome immune suppression in brain tumors.

Area of Science:

  • Neuro-oncology
  • Immunology
  • Cancer Therapy

Background:

  • Glioblastoma (GBM) is a deadly primary brain tumor with limited treatment options.
  • The brain's immune privilege is a misconception; GBM actively suppresses immune responses.
  • Immunotherapy is a rapidly advancing field in oncology.

Purpose of the Study:

  • To review the current clinical development of immunotherapeutics for GBM.
  • To discuss challenges in applying immunotherapy to brain tumors.
  • To explore the potential of vaccines, cell-based therapies, and immune checkpoint modulators for GBM.

Main Methods:

  • Review of current preclinical and clinical data on GBM immunotherapy.
  • Analysis of mechanisms of immune suppression in GBM.

Related Experiment Videos

  • Summary of ongoing clinical trials.

    • Main Results:

    • Emerging preclinical and clinical data suggest immunotherapy's potential for GBM.
    • GBM utilizes multiple mechanisms to evade immune detection and destruction.
    • Initial clinical trials are expected to provide preliminary efficacy data.

    Conclusions:

    • The role of immunotherapy in GBM treatment is under active investigation.
    • Overcoming GBM's immune-suppressive microenvironment is critical.
    • Future GBM immunotherapy strategies will likely involve rationally designed combination regimens.